Abstracts tagged "rituximab and vasculitis"

Abstract Number: 2079 • 2016 ACR/ARHP Annual Meeting
Incidence and Risk of Pneumocystis Jirovecii Pneumonia Following Rituximab Treatment in Granulomatosis with Polyangiitis in the United States: An Analysis from a National Database
Sirada Panupattanapong¹, Anthony R. French², Andrew J. White², Margaret A. Olsen³, Maya Rendulic⁴ and Mary E. Hartman⁵, ¹Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ²Division of Pediatric Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ³Division of Infectious Disease, Washington University School of Medicine, St. Louis, MO, ⁴Center for Administrative Data Research, Washington University School of Medicine, St. Louis, MO, ⁵Division of Pediatric Critical Care Medicine, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO
Background/Purpose: Pneumocystis Jirovecii pneumonia (PJP) is a life-threatening complication in granulomatosis with polyangiitis (GPA). Guidelines from EULAR for ANCA-associated vasculitis (AAV) recommend institution of PJP…
Abstract Number: 1991 • 2015 ACR/ARHP Annual Meeting
Large Vessel Involvement By IgG4-Related Disease
Cory Perugino¹, Zachary Wallace¹ and John H. Stone², ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory condition of uncertain etiology. Reports have described inflammatory aortitis and peri-aortitis in the setting of retroperitoneal fibrosis…
Abstract Number: 2855 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Rituximab Retreatment Regimen at Clinical Relapse in Severe Cryoglobulinemic Vasculitis
Luca Quartuccio¹, Francesca Zuliani², Patrizia Scaini³, Marco Lenzi⁴, Antonio Tavoni⁵, Marco Sebastiani⁶, Teresa Urraro⁷, Francesco Saccardo⁸, Costanza Sbreglia⁹, Pietro Pioltelli¹⁰, Paolo Fraticelli¹¹, Davide Filippini¹², Salvatore Scarpato¹³, Oreste Perrella⁹, Armando Gabrielli¹⁴, Dario Roccatello¹⁵, Anna Linda Zignego¹⁶, Clodoveo Ferri¹⁷, Stefano Bombardieri¹⁸, Maurizio Pietrogrande¹⁹, Massimo Galli²⁰, Giuseppe Monti⁸ and Salvatore De Vita¹, ¹Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ²Rheumatology Clinic, University Hospital of Udine, Udine, Italy, ³Nephrology, Spedali Civili di Brescia, Brescia, Italy, ⁴University of Bologna, Bologna, Italy, ⁵Rheumatology Clinic, University of Pisa, Pisa, Italy, ⁶Rheumatology Clinic, University of Modena and Reggio Emilia, Modena, Italy, ⁷Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁸Internal Medicine Unit, Saronno Hospital, Azienda Ospedaliera di Busto Arsizio, Saronno (VA), Italy, ⁹Rheumatology Unit, AO Cotugno, Naples, Italy, ¹⁰Hematology, S.Gerardo Hospital, Monza, Italy, ¹¹Istituto di Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, ¹²Rheumatology Unit, Ospedale Niguarda Ca’ Granda, Milan, Italy, ¹³Rheumatology Unit, M. Scarlato Hospital, Scafati, Salerno, Italy, ¹⁴Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy, ¹⁵CORSO RAFFAELLO 30, UNIVERSITY OF TURIN (ITALY), TURIN, Italy, ¹⁶University of Florence, Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹⁷Internal Med/Rheumatology, Univ Modena Reggio Emilia, Modena, Italy, ¹⁸Rheumatology Unit, University of Pisa, Pisa, Italy, ¹⁹Internal Medicine Unit, Policlinico San Marco, Bergamo, Italy, ²⁰Istituto di Malattie Infettive e Tropicali, Università di Milano c/o Ospedale L. Sacco, Milano, Italy
Background/Purpose: Two independent controlled randomized trials recently reported the efficacy and safety of rituximab (RTX) monotherapy in severe cryoglobulinemic vasculitis (CV) (1, 2), with one…
Abstract Number: 1776 • 2014 ACR/ARHP Annual Meeting
Factors Predictive of ANCA-Associated Vasculitis Relapse in Patients Given Rituximab-Maintenance Therapy
Benjamin Terrier¹, Christian Pagnoux², Guillaume Geri³, Alexandre Karras⁴, Chahéra Khouatra⁵, Olivier Aumaitre⁶, Pascal Cohen⁷, Francois Maurier⁸, Olivier Decaux⁹, Hélène Desmurs-Clavel¹⁰, Pierre Gobert¹¹, Thomas Quemeneur¹², Claire Blanchard-Delaunay¹³, Pascal Godmer¹⁴, Xavier Puéchal⁷, Luc Mouthon⁷ and Loïc Guillevin for the French Vasculitis Study Group⁷, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³Intensive Care Unit, Cochin Hospital, Paris, France, ⁴Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁵CHU Louis Pradel, Lyon, Lyon, France, ⁶Internal Medicine, CHU, Clermont-Ferrand, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁸HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁹Department of Internal Medicine, Rennes University Hospital, Rennes, France, ¹⁰University of Lyon, LYON, France, ¹¹Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹²Internal Medicine, CH, Valenciennes, France, ¹³Internal Medicine, Hôpital de Niort, Niort, France, ¹⁴Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France
Background/Purpose Rituximab (RTX) was shown to be as effective as cyclophosphamide to induce remission in patients with ANCA-associated vasculitis (AAV). The prospective MAINRITSAN trial compared…
Abstract Number: 1754 • 2014 ACR/ARHP Annual Meeting
Peripheral CD5⁺b-Cells in ANCA-Associated Vasculitis
Sebastian Unizony¹, Noha Lim², Vincent Carey³, Deborah J. Phippard², Nadia Tchao², Eli M. Miloslavsky⁴, Peter A. Merkel⁵, Paul Monach⁶, William St. Clair⁷, Robert F. Spiera⁸, Adam Asare², Philip Seo⁹, Carol A. Langford¹⁰, Gary S. Hoffman¹¹, Cees Kallenberg¹², Ulrich Specks¹³ and John H. Stone⁴, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Immune Tolerance Network, Bethesda, MD, ³Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Massachusetts General Hospital, Boston, MA, ⁵Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, Boston University, Boston, MA, ⁷Rheumatology and Immunology, Duke University, Durham, NC, ⁸Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁰Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ¹²Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ¹³Frederichs Dr NW, Mayo Clinic, Rochester, MN
Background/Purpose We explored the utility of peripheral CD19+ CD5+ B-cells (CD5+ B-cells) as biomarkers in ANCA-associated vasculitis (AAV) Methods CD5+ B-cells were measured longitudinally by…
Abstract Number: 2640 • 2013 ACR/ARHP Annual Meeting
VERY LONG-TERM Effects Of The “4 PLUS2 Infusion PROTOCOL” Of Rituximabalone In Patients With HCV-Associatedmixed Cryoglobulinemia With Diffusemembranoproliferative Glomerulonephritis,Severe Polyneuropathy and Necrotic Ulcersof Skin
Dario Roccatello¹, Savino Sciascia¹, Simone Baldovino² and Daniela Rossi¹, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Centro di Ricerche di Immunologia Clinica ed Immunopatologia e Documentazione su Malattie Rare (CMID), Università di Torino, Torino, Italy
Background/Purpose: Mixed cryoglobulinemia syndrome (MCs) is a systemic vasculitischaracterized by multiple organ involvement due to the vascular deposition ofIgMk/IgG cryoglobulins. B cells expansion usually triggered…
Abstract Number: 1646 • 2013 ACR/ARHP Annual Meeting
Alterations In Circulating T Follicular Helper Cells and T Regulatory Cells In Autoimmune Rheumatic Diseases Treated With B Cell Depletion Therapy: Rituximab
Pamela M.K Lutalo^1,2, Yuan Zhao², Lee Meng Choong¹, Shirish Sangle¹, Jo Spencer³ and David P. D'Cruz⁴, ¹Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, ²Peter Gorer Department of Immunobiology, School of Medicine, King's College London, London, United Kingdom, ³Peter Gorer Department of Immunobiology, King's College London, School of Medicine, London, United Kingdom, ⁴Louise Coote Lupus Unit, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom
Background/Purpose: Granulomatosis with polyangiitis (GPA) and systemic lupus erythematosus (SLE) are autoimmune rheumatic diseases which develop due to failure of immune self-tolerance. T follicular helper…
Abstract Number: 744 • 2013 ACR/ARHP Annual Meeting
Relationship Between Infectious Side Effects and Immunoglobulin Levels In The Maintenance Rituximab Vs Azathioprine For ANCA-Associated Vasculitides Trial
Loic Guillevin¹, Christian Pagnoux², Alexandre Karras³, Chahera Khouatra⁴, Olivier Aumaître⁵, Pascal Cohen⁶, Olivier Decaux⁷, Hélène Desmurs-Clavel⁸, Pierre Gobert⁹, Thomas Quemeneur¹⁰, Claire Blanchard-Delaunay¹¹, Pascal Godmer¹², Xavier Puechal¹³, Pierre-Louis Carron¹⁴, Pierre-Yves Hatron¹⁵, Nicolas Limal¹⁶, Mohamed Hamidou¹⁷, Francois Maurier¹⁸, Thomas Papo¹⁹, Matthias Büchler²⁰, Bernard Bonnotte²¹, Philippe Ravaud²² and Luc Mouthon²³, ¹Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ²Internal Medicine, Hôpital Cochin, PARIS, France, ³Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁴CHU Lyon, Lyon, France, ⁵Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁷Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁸University of Lyon, LYON, France, ⁹Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹⁰Internal medicine, CHR de Valenciennes, Valenciennes, France, ¹¹Internal Medicine, Hôpital de Niort, Niort, France, ¹²Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁴Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, ¹⁵Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹⁶Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ¹⁷Internal Medicine Department, Nantes University Hospital, Nantes, France, ¹⁸HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ¹⁹Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, ²⁰Nephrology, University Hospital of Tours, TOURS, France, ²¹Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, ²²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ²³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: MAINRITSAN trial (NCT 00748644) results demonstrated that 500 mg of rituximab (RTX) every 6 months was superior to azathioprine (AZA) to maintain ANCA-associated–vasculitis (AAV)…
Abstract Number: 2596 • 2012 ACR/ARHP Annual Meeting
Rituximab Treatment for Antineutrophil Cytoplasmic Antibody – Associated Vasculitis in Children
Katharine F. Moore¹, Leonard L. Dragone², Jennifer B. Soep³ and J. Roger Hollister⁴, ¹Pediatric Rheumatology, Seattle Children's Hospital / University of Washington, Seattle, WA, ²Dept of Pediatrics, National Jewish Health, Denver, CO, ³Pediatric Rheumatology, Children's Hospital Colorado, Aurora, CO, ⁴Dept of Pediatrics, Children's Hospital Colorado, Aurora, CO
Background/Purpose: The purpose of this study was to report the experience of a tertiary-care children’s hospital using rituximab in the treatment of pediatric antineutrophil cytoplasmic…
Abstract Number: 2383 • 2012 ACR/ARHP Annual Meeting
Rituximab As Induction and Maintenance Therapies for ANCA-Associated Vasculitis: A Multicenter Retrospective Study On 80 Patients
Pierre Charles¹, Antoine Néel², Nathalie Tieulié³, Arnaud Hot⁴, Grégory Pugnet⁵, Olivier Decaux⁶, Isabelle Marie⁷, Mehdi Khellaf⁸, Jean-Emmanuel Kahn⁹, Alexandre Karras¹⁰, Jean-Marc Ziza¹¹, Christophe Deligny¹², Colas Tchérakian¹³ and Loic Guillevin¹⁴, ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²Internal Medicine, Nantes University Hospital, Nantes, France, ³CHU Nice, Nice, France, ⁴Internal Medicine, Edouard Herriot University Hospital, Lyon, France, ⁵Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ⁶Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁷Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, ⁸Internal Medicine, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, ⁹Internal Medicine, Foch Hospital, Suresnes, France, ¹⁰Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ¹¹Rheumatology, Croix Saint Simon Hospital, Paris, France, ¹²Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, ¹³Service de pneumologie, hôpital Foch, Suresnes, France, ¹⁴Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Rituximab has been shown to induce remission of ANCA-associated vasculitis (AAV). Our study was undertaken to 1) describe the clinical response of AAV to…
Abstract Number: 1652 • 2012 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
Loic Guillevin¹, Christian Pagnoux², Alexandre Karras³, Chahera Khoutra⁴, Olivier Aumaitre⁵, Pascal Cohen⁶, Francois Maurier⁷, Olivier Decaux⁸, Hélène Desmurs-Clavel⁹, Pierre Gobert¹⁰, Thomas Quemeneur¹¹, Claire Blanchard-Delaunay¹², Pascal Godmer¹³, Xavier Puechal¹⁴, Pierre-Louis Carron¹⁵, Pierre yves Hatron¹⁶, Nicolas Limal¹⁷, Mohamed Hamidou¹⁸, Maize Ducret¹⁹, Florence Vende²⁰, Elisa Pasqualoni²¹, Bernard Bonnotte²², Philippe Ravaud²³, Luc Mouthon²⁴ and French Vasculitis Study Group (FVSG)²⁵, ¹Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ²Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ³Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁴Pneumology, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, ⁵Department of Internal Medicine, Centre Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁷HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁸Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁹Internal Medicine, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, ¹⁰Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹¹Internal medicine, CHR de Valenciennes, Valenciennes, France, ¹²Internal Medicine, Centre Hospitalier, Niort, France, ¹³Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹⁴Internal Medicine, Hôpital Cochin, Paris, France, ¹⁵Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, ¹⁶Department of Internal Medicine, Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, ¹⁷Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ¹⁸Internal Medicine Department, Nantes University Hospital, Nantes, France, ¹⁹Department of Internal Medicine, Centre Hospitalier d'Annecy, Annecy, France, ²⁰Nephrology, Hôpital Bicbat, APHP, Paris, France, ²¹Department of Internal Medicine, Hôpital Bicbat, APHP, Paris, France, ²²Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, ²³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ²⁴Internal Medicine, Hopital Cochin, Paris, France, ²⁵Internal Medicine, Hôpital Cochin, Université Paris–Descartes, Paris, France
Background/Purpose: Once ANCA-associated vasculitis (AAV) remission has been achieved with CS and cyclophosphamide (CYC), maintenance therapy usually relies on azathioprine (AZA) or methotrexate. However, 18-…
Abstract Number: 1542 • 2012 ACR/ARHP Annual Meeting
The Efficacy of Rituximab Vs Cyclophosphamide for Treatment of Renal Disease in ANCA-Associated Vasculitis: The RAVE Trial Geetha D, Fervenza FC for the RAVE-Itn Research Group
Duvuru Geetha¹ and Fernando Fervenza², ¹Nephrology, Johns Hopkins University, Baltimore, MD, ²Mayo Clinic, Rochester, MN
Background/Purpose: Rituximab (RTX) is non-inferior to cyclophosphamide (CYC) followed by azathioprine (AZA) for remission-induction in severe ANCA associated vasculitis (AAV) but details of outcomes among…
Abstract Number: 1543 • 2012 ACR/ARHP Annual Meeting
Rituximab for ANCA-Associated Vasculitis: A Meta-Analysis of Randomized Trials
Carolina Mejia¹ and Carlos J. Lozada², ¹Internal Medicine, Mount Sinai Medical Center, Miami, FL, ²Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Background/Purpose: Over the past 40 years, cyclophosphamide/glucocorticoids combination therapy has been the standard regimen for remission induction in ANCA-associated vasculitis.. Although a major advance in…
Abstract Number: 1547 • 2012 ACR/ARHP Annual Meeting
A 4 Plus 2 Infusion Protocol of Rituximab Provides Long-Term Beneficial Effects in Patients with HCV-Associated Mixed Cryoglobulinemia with Membranoproliferative Nephritis and Severe Polyneuropathy
Dario Roccatello¹, Savino Sciascia², Simone Baldovino³ and Daniela Rossi¹, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ³Centro di Ricerche di Immunologia Clinica ed Immunopatologia e Documentazione su Malattie Rare (CMID), Università di Torino, Torino, Italy
Background/Purpose: Mixed cryoglobulinemia syndrome (MCs) is a systemic vasculitis characterized by multiple organ involvement due to the vascular deposition of immune-complexes, mainly the cryoglobulins. B…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].